ADCs & Cancer Immunotherapy

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.


Key Practical Learning Points of the Summit:

  • Increase benefits of ADC-dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness
  • Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
  • Learn about advances in protein modelling and engineering breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
  • Linker design decisions, novel payloads and linker technology, next-generation chemistry for improved conjugation and linker stability
  • Characterization of ADCs, preclinical and clinical advances, translational considerations
  • Engineering ADCs for developability, enhanced specificity and binding, and reduced toxicity

Who Should Attend:

CEOs, Directors, Department Heads & Managers of Leading Application Creators & Suppliers from:

  • Discovery Chemistry
  • Research & Development
  • Antibody Discovery
  • Protein Engineering
  • Oncology Molecules
  • Biopharmaceutical Development
  • Development Analytics and New Technologies
  • Toxicology
  • Molecular Biology
  • Technology
  • Biotherapeutics
  • Molecular Medicine
  • Data analysis
  • Analytical & Formulation
  • Oncology Drug Development
  • Medical information
  • Bioanalytical
  • Process Sciences
  • Clinical Assay

From Industries Including: 

  • Pharmaceuticals, Biologics, Medicine
  • Clinical Research Organizations
  • Academic Research Centers
  • Regulatory Agencies


Media partners